Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Clinical trial NCT04592653 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04592653
- Sponsor
- Mural Oncology, Inc
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-30
- Primary completion
- 2024-07-01
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.